Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Comparison of Efficacy of Sugammadex Versus Neostigmine in Reversing Neuromuscular Blocks in Patients Having Outpatient Endoscopic Retrograde Cholangiopancreatography (ERCP). A Randomized, Double-Blinded Trial
The Cleveland Clinic
80 participants
Jun 1, 2024
INTERVENTIONAL
Conditions
Summary
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.
Eligibility
Inclusion Criteria3
- ≥18 years old
- American Society of Anesthesiologist physical status 3-4
- Scheduled for outpatient endoscopic retrograde cholangiopancreatography
Exclusion Criteria8
- Difficult Airway
- Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)
- End stage renal disease requiring dialysis
- Pregnancy or breast-feeding
- Allergy to Fentanyl
- Allergy to Neuromuscular blocking drugs (eg: rocuronium)
- Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)
- Allergy to glycopyrrolate
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 2 mg/kg sugammadex.
All participants will be given rocuromium for neuromuscular blocks during the procedure. Per randomization, patients in this group will be reversed with 0.07 mg/kg neostigmine (to a maximum of 5 mg).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06136585